Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2429-2429
Open Access | Times Cited: 75

Showing 26-50 of 75 citing articles:

Epidemiology of carcinomatosis
Kyle Mani, Jun Lu, Eric J. Lehrer, et al.
Cancer Epidemiology (2025) Vol. 97, pp. 102815-102815
Closed Access
Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation
Yu‐Li Lo, Ching-Yao Li, Tsui‐Fen Chou, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116660-116660
Open Access | Times Cited: 3
ARMCX3 regulates ROS signaling, affects neural differentiation and inflammatory microenvironment in dental pulp stem cells
Quanying Zhou, Yi Lei
Heliyon (2024) Vol. 10, Iss. 17, pp. e37079-e37079
Open Access | Times Cited: 3
Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization
Liuliu Quan, Jinsong Liu, Yuxin Wang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer
Akash Bararia, Prosenjeet Chakraborty, Paromita Roy, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 15, pp. 2241-2260
Open Access | Times Cited: 8
The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma
Mahshid Panahi, Fereshteh Rezagholizadeh, Shabnam Mollazadehghomi, et al.
Cancer Treatment and Research Communications (2023) Vol. 35, pp. 100699-100699
Open Access | Times Cited: 7
A Comprehensive Transcriptional Signature in Pancreatic Ductal Adenocarcinoma Reveals New Insights into the Immune and Desmoplastic Microenvironments
Irene Pérez-Díez, Zoraida Andreu, Marta R. Hidalgo, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2887-2887
Open Access | Times Cited: 7
Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy
Wanting Hou, Biao Yang, Hong Zhu
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 2033-2033
Open Access | Times Cited: 12
TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth
Amrendra K. Ajay, Martin Gasser, Li‐Li Hsiao, et al.
Antibodies (2024) Vol. 13, Iss. 1, pp. 11-11
Open Access | Times Cited: 2
Explainable cancer factors discovery: Shapley additive explanation for machine learning models demonstrates the best practices in the case of pancreatic cancer
Liuyan Su, Alphonse Houssou Hounye, Q. Allab Pan, et al.
Pancreatology (2024) Vol. 24, Iss. 3, pp. 404-423
Closed Access | Times Cited: 2
A prognostic model for anoikis-related genes in pancreatic cancer
Wenbin Song, Haiyang Hu, Zhengbo Yuan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
Shiqiong Zhou, Peng Wan, Sen Zhang, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 7, pp. 859-866
Open Access | Times Cited: 2
A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumors
Grace A. McCarthy, Aditi Jain, Roberto Di Niro, et al.
Translational Oncology (2023) Vol. 32, pp. 101662-101662
Open Access | Times Cited: 6
Targeting Periostin Expression Makes Pancreatic Cancer Spheroids More Vulnerable to Natural Killer Cells
Didem Karakaş, Merve Erkısa, Remzi Okan Akar, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 270-270
Open Access | Times Cited: 5
Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma
Sarah Mansouri, Lauren Daniel, Nawal Amhis, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance
C.J. Grobbelaar, Mpho Kgomo, Peace Mabeta
Current Cancer Drug Targets (2024) Vol. 24, Iss. 11, pp. 1116-1127
Closed Access | Times Cited: 1
Nano-Pulse Stimulation Treatment Inhibits Pan02 Murine Pancreatic Tumor Growth and Induces a Long-Term Adaptive Immune Response with Abscopal Effects When Combined with Immune-Enhancing Agents
Amanda McDaniel, Kristin Von Rothstein, Dacia Gonzalez, et al.
Bioelectricity (2024) Vol. 6, Iss. 2, pp. 108-117
Closed Access | Times Cited: 1
The molecular evidence behind the adjunct use of anticoagulants and chemotherapy in pancreatic cancer treatment: A new role for anticoagulants?
Ghena Lababidi, Noura Wahoud, Lina Ghandour, et al.
Human Gene (2024) Vol. 41, pp. 201307-201307
Closed Access | Times Cited: 1
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?
Charalampos Theocharopoulos, Ioannis A. Ziogas, Charalampos-Christos Douligeris, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102806-102806
Closed Access | Times Cited: 1
Multiple Comprehensive Analyses Identify Lysine Demethylase KDM as a Potential Therapeutic Target for Pancreatic Cancer
Wan‐Jou Shen, Hsuan-Min Kao, Chih‐Yang Wang, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 11, pp. 2158-2169
Open Access | Times Cited: 1
Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi‐omics analysis
Tomoaki Toyoda, Nami Miura, Shingo Kato, et al.
Cancer Science (2024)
Open Access | Times Cited: 1
First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review
Yazhou Wang, Mao-Zhen Peng, Yao-Lin Xu, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
A single-cell perspective on immunotherapy for pancreatic cancer: from microenvironment analysis to therapeutic strategy innovation
Rui Wang, Jie Liu, Bo Jiang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Human serum albumin promotes interactions between HSA-IL-2 fusion protein and CD122 for enhancing immunotherapy
Kaiyue Zuo, Naiyu Liu, Peng Zhou, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 181, pp. 117664-117664
Closed Access | Times Cited: 1
Comprehensive Pan-cancer analysis of CD73: explore its association with prognosis and tumor immune microenvironment
Chen Chen, S. Liu, Yanfen Ma
Heliyon (2024) Vol. 10, Iss. 22, pp. e40329-e40329
Open Access | Times Cited: 1

Scroll to top